Interleukin 17, the double-edged sword in atherosclerosis |
| |
| Affiliation: | 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran;3. School of Medicine, Iran University of Medical Sciences, Tehran, Iran;4. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran;5. Research Center for Immunodeficiencies, Children''s Medical Center, Tehran University of Medical Sciences, Tehran, Iran;6. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;1. Tianjin Eye Hospital, Tianjin Key Laboratory of Ophthalmology and Vision Science, Nankai University Eye Hospital, Clinical College of Ophthalmology, Tianjin Medical University, Tianjin 300020, PR China;2. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Tianjin Medical University Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, PR China;3. Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, PR China;1. Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark;2. National Veterinary Institute, Technical University of Denmark, Kgs. Lyngby, Denmark;3. Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark;4. Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark;5. Faculty of Veterinary Medicine, Ghent University, Belgium;1. Department of Pediatrics, School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China;2. Department of Pediatrics, Zhongda Hospital, Southeast University, Nanjing 210009, Jiangsu, China;3. Department of Pediatrics, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University, Nanjing 210093, Jiangsu, China;4. Department of Pediatrics, Jinling Hospital, Nanjing Medical University, Nanjing 210093, Jiangsu, China;1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, 200025 Shanghai, China;2. Pôle de Recherches Sino-Français en Science du Vivant et Génomique, 197 Rui Jin Er Road, 200025 Shanghai, China;3. CNRS UMR 5309/INSERM U1209/Université Grenoble-Alpes/Institute for Advanced Biosciences, 38700 La Tronche, France |
| |
| Abstract: | Cardiovascular diseases, including atherosclerosis, are the number one cause of death worldwide. These diseases have taken the place of pneumonia and other infectious diseases in the epidemiological charts. Thus, their importance should not be underestimated. Atherosclerosis is an inflammatory disease. Therefore, immunological signaling molecules and immune cells carry out a central role in its etiology. One of these signaling molecules is interleukin (IL)-17. This relatively newly discovered signaling molecule might have a dual role as acting both pro-atherogenic and anti-atherogenic depending on the situation. The majority of articles have discussed IL-17 and its action in atherosclerosis, and it may be a new target for the treatment of patients with this disease. In this review, the immunological basis of atherosclerosis with an emphasis on the role of IL-17 and a brief explanation of the role of IL-17 on atherosclerogenic disorders will be discussed. |
| |
| Keywords: | IL-17 Atherosclerosis Cytokines Macrophage T helper cells |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
